Precigen, Inc.
PGEN
Jodie situation report
Precigen, Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 14 directly disclosed connections are confirming.
- At least 15 of 23 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- BMRN remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.
Who this business touches
The relationships behind PGEN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PTCTPTC Therapeutics, Inc.partnerNov 13, 2025 ▾
“In September 2025, the Company and PTC Therapeutics mutually agreed to terminate their existing exclusive channel collaboration ("ECC") agreement.”
ABBVAbbVie Inc.competitorMar 25, 2026 ▾
“We also face competition from non-cell based cancer treatments offered by other companies such as Amgen, AstraZeneca, Merck, Abbvie, and Roche.”
AMGNAmgen Inc.competitorMar 25, 2026 ▾
“We also face competition from non-cell based cancer treatments offered by other companies such as Amgen, AstraZeneca, Merck, Abbvie, and Roche.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PGEN is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.